Camber1jpj (Camber1jpg)
Tadalafil
Product Images NDC 71335-1239
11 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image (Lbl713351239)
Label for Tadalafil 20 mg tablet by Bryant Ranch Prepack, NDC 71335-1239. The label states it is a white capsule marked T15;H and compares the product to Cialis 20 mg tablet by Hetero Labs Limited. It includes storage instructions to keep at room temperature (20°-25°C) and a warning to keep drugs out of reach of children. The package appears to contain 30 tablets.*
Tadalafilfigure1.jpg (Tadalafilfigure1)
Four line graphs depicting blood pressure changes over time (hours) for Tadalafil versus placebo. The graphs are titled Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, showing differences in mmHg with error bars across multiple time points up to 96 hours.*
Tadalafilfigure2.jpg (Tadalafilfigure2)
A two-panel line graph showing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours post-dose. The upper panel displays standing systolic blood pressure changes; the lower panel shows supine systolic blood pressure changes. Time post-dose in hours is on the x-axis, and blood pressure change in mmHg is on the y-axis.*
Tadalafilfigure4.jpg (Tadalafilfigure4)
A line graph showing the systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo in combination with doxazosin. Four lines represent 20 mg tadalafil at 08:00 and 20:00 with 8 mg qd doxazosin, and placebo at 08:00 and 20:00 with 8 mg qd doxazosin. The x-axis is time after administration, and the y-axis is systolic blood pressure.*
Tadalafilfigure5.jpg (Tadalafilfigure5)
A pharmacokinetic plot displaying plasma tadalafil concentration (µg/L) over time (hours). The graph compares three dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. Concentration decreases over time with distinct profiles for each dosing condition.*
Tadalfilfigure6.jpg (Tadalafilfigure6)
A line graph showing change from baseline in IPSS Total Score over treatment duration in weeks (0, 4, 8, 12) comparing Tadalafil 5 mg to placebo. Tadalafil shows a greater decrease in IPSS score over time compared to placebo, with a statistically significant difference indicated at p<0.01.*
Tadalafilfigure7.jpg (Tadalafilfigure7)
A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis shows duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score. Tadalafil shows a greater decrease in score compared to placebo, with significant changes marked.*
Tadalafilfigure8 (Tadalafilfigure8)
A chart plotting the least squares mean change from baseline over weeks of therapy (0 to 26 weeks) comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph depicts mean changes with data points at 4, 12, and 26 weeks, showing Tadalafil/Finasteride consistently having a greater negative change than placebo. Statistical significance markers for p<0.001 and p<0.05 are noted.*
Tadalfilfigure9.jpg (Tadalafilfigure9)
Line graph comparing change from baseline in IPSS total score over 12 weeks between Tadalafil and placebo treatments. The x-axis shows treatment duration in weeks, and the y-axis shows score change, with Tadalafil showing a greater reduction over time compared to placebo.*
Tadalafilstructure.jpg (Tadalafilstructure)
Chemical structure diagram of tadalafil. The image shows the molecular arrangement including its fused ring system and key functional groups as commonly represented in pharmaceutical labeling.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
